New Research Suggests Type 1 Diabetes May Respond to Different Immune Therapies Depending on Subtype

Scientists analyzing blood samples from hundreds of people newly diagnosed with Type 1 diabetes have identified two distinct immune subtypes that appear to respond better to different immunotherapy approaches. This early discovery could one day help doctors match patients to treatments more effectively.

Video report, corroborated with 5 indexed studies

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Researchers found evidence that Type 1 diabetes may involve at least two different immune subtypes, each with distinct characteristics and treatment responses.
One subtype, often found in younger people who lose insulin-producing cells more rapidly, responded better to an anti-CD20 drug in clinical trials.
The other subtype showed better results with a different immune therapy approach.
This is laboratory-based research that demonstrates potential—there is no patient test available yet to identify which subtype a person has.
If confirmed in future studies, personalized matching of patients to the right immunotherapy could improve treatment effectiveness.

One Disease or Two?

For decades, Type 1 diabetes has been understood as a single autoimmune condition: the body's immune system mistakenly attacks the insulin-producing beta cells in the pancreas. New research challenges that assumption. Scientists analyzed blood samples from 560 people across six different immunotherapy trials and found evidence of two distinct immune subtypes within the newly diagnosed population.

This discovery matters because it could explain why some people respond well to certain immune therapies while others do not. Understanding these differences might eventually allow doctors to recommend the treatment most likely to work for each person's unique immune profile.

What the Study Found

One subtype tended to include younger patients who were losing insulin-producing cells at a faster rate. This group showed better responses to an anti-CD20 drug—an immunotherapy that targets B cells, a type of immune cell involved in autoimmunity.

The second subtype responded more effectively to a different immune therapy approach. The researchers did not specify which therapy in the available information, but the key finding is that responses differed between groups.

The research was published in the journal Diabetologia in July 2026 and represents an analysis across multiple clinical trials, giving it more weight than a single small study.

What This Means Now—and Later

This is important to emphasize: this research is based on laboratory analysis of blood samples and does not translate immediately into clinical practice. There is currently no test available to identify which immune subtype a person has, nor any change to how Type 1 diabetes treatment is recommended at this stage.

However, the findings point toward a future direction. If these immune subtypes can be reliably identified and validated in larger studies, doctors might one day use that information to select the immunotherapy most likely to work for each individual—a step toward more personalized medicine in Type 1 diabetes.

This aligns with broader research efforts to understand the biology of Type 1 diabetes more deeply and to move beyond treating it as a one-size-fits-all condition. As always, anyone considering immunotherapy or any other treatment should discuss their options thoroughly with their care team.

Evidence label

Origin: YouTube / T1D Pulse (Video report). Evidence: Video report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.